Regulatory Considerations For An Optimized Cold Chain
Source: Charter Medical
Here, Umoja's Co-Founder and CTO Ryan Crisman and BMS’ Global Head, Cell Therapy Logistics and Shipping Systems, Rookie Gleich detail some of the cold chain for cell therapies is beholden to regulatory requirements.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Charter Medical
This website uses cookies to ensure you get the best experience on our website. Learn more